NYSE : JNJ
Johnson & Johnson — Key statistics
Healthcare · Drug Manufacturers - General · United States
Last price 275.2 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 662.49B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 657.68B |
| Enterprise Value | 685.10B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 13, 2026 |
| Ex-Dividend Date | Nov 24, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.41B |
| Shares Outstanding | 2.41B |
| Shares Change (YoY) | +0.80% |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 76.26% |
| Float | 2.40B |
Ratios
| Measure | Value |
|---|
| PE Ratio | 41.49 |
| Forward PE | 24.56 |
| PS Ratio | 6.62 |
| Forward PS | 6.22 |
| PB Ratio | 8.07 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 31.94 |
| P/OCF Ratio | 25.14 |
| PEG Ratio | 3.34 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 42.57 |
| EV / Sales | 6.90 |
| EV / EBITDA | 19.86 |
| EV / EBIT | 25.94 |
| EV / FCF | 33.27 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.02 |
| Quick Ratio | 0.65 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | 1.29 |
| Debt / FCF | 2.17 |
| Interest Coverage | 26.84 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 20.02% |
| Return on Assets (ROA) | 8.46% |
| Return on Invested Capital (ROIC) | 21.57% |
| Return on Capital Employed (ROCE) | 18.60% |
| Weighted Average Cost of Capital (WACC) | 5.17% |
| Revenue Per Employee | $718,777 |
| Profits Per Employee | $116,462 |
| Employee Count | 138,200 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.17 |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.64B |
| Effective Tax Rate | 9.26% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +46.41% |
| 50-Day Moving Average | 265.60 |
| 200-Day Moving Average | 246.99 |
| Relative Strength Index (RSI) | 60.35 |
| Average Volume (20 Days) | 7,495,123 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 16.77M |
| Short Previous Month | 21.19M |
| Short % of Shares Out | 0.70% |
| Short % of Float | 0.70% |
| Short Ratio (days to cover) | 2.23 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 99.34B |
| Gross Profit | 67.32B |
| Operating Income | 26.41B |
| Pretax Income | 17.74B |
| Net Income | 16.10B |
| EBITDA | 34.50B |
| EBIT | 26.41B |
| Earnings Per Share (EPS) | $6.58 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 17.23B |
| Total Debt | 44.65B |
| Net Cash | -27.42B |
| Net Cash Per Share | -$11.39 |
| Equity (Book Value) | 81.53B |
| Book Value Per Share | 33.87 |
| Working Capital | 894.00M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 26.16B |
| Capital Expenditures | -5.57B |
| Depreciation & Amortization | 8.09B |
| Net Borrowing | -787.00M |
| Free Cash Flow | 20.59B |
| FCF Per Share | $8.55 |
Margins
| Measure | Value |
|---|
| Gross Margin | 67.77% |
| Operating Margin | 26.59% |
| Pretax Margin | 17.86% |
| Profit Margin | 16.20% |
| EBITDA Margin | 34.73% |
| EBIT Margin | 26.59% |
| FCF Margin | 20.73% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $5.36 |
| Dividend Yield | 1.96% |
| Dividend Growth (YoY) | 3.50% |
| Years of Dividend Growth | 64 |
| Payout Ratio | 81.40% |
| FCF Payout Ratio | 62.67% |
| Buyback Yield | -0.80% |
| Shareholder Yield | 1.17% |
| Earnings Yield | 2.41% |
| FCF Yield | 3.13% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $279.41 |
| Price Target Difference | 2.27% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (3Y) | 7.34% |
| EPS Growth Forecast (3Y) | 8.87% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 13, 2001 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 5.03 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |